Denmark is negotiating with the US regarding a potential deal involving Greenland, but its largest industry, pharmaceuticals, may lack leverage. Novo Nordisk, a key player in weight loss drugs, holds a significant US market share. Experts warn that restrictions on Danish products could backfire, as semaglutide, the active ingredient in popular drugs, is not essential like antibiotics. The US market is crucial for Novo Nordisk, and any restrictions could lead to shortages and the emergence of unapproved versions of the drug. Teljes cikk (Euronews.com)